Recurrent Injury, Death Common After Acute Firearm Injury
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
THURSDAY, Aug. 31, 2023 -- Recurrent injury and death are common among acutely firearm-injured patients in the United States, according to a study published online Aug. 29 in the Annals of Internal Medicine.
Kristen L. Mueller, M.D., from Washington University in St. Louis, and colleagues examined the incidence and factors associated with recurrent firearm injuries and death among 9,553 consecutive adult and pediatric patients presenting with an acute, nonfatal firearm injury.
The researchers found that 1,155 patients experienced a recurrent firearm injury during a median follow-up of 3.5 years, including five firearm suicides and 149 fatal firearm injuries. Persons experiencing recurrent injury were young (25.3 ± 9.5 years), mostly male (93 percent), Black (96 percent), and uninsured (50 percent). The majority lived in areas of high social vulnerability (65 percent). The estimated risk for firearm injury at one and eight years was 7 and 17 percent, respectively.
"These data provide robust estimates of the burden of recurrent firearm injury and highlight the need for cross-sector data sharing to support firearm injury reduction," the authors write. "Accurate estimates of recurrence rates enhance both the ability to design appropriate violence intervention programs and to evaluate their real-world effectiveness, yet few studies have addressed firearm injury recurrence."
One author disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted August 2023
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.